Australia, Aug. 25 -- NextCell Pharma AB, owns the trademark (2620733) for 'NXTCL' till Dec. 8, 2035.

Status: protected: Registered/protected

Classes: 1 [Chemicals used in science; stem cells for research purposes; stem cells for scientific purposes; cell growth media for growing cells for scientific use; biological preparations [other than for medical use]; cultures of cell media [other than for medical or veterinary use].], 5 [Live organs and tissues for surgical purposes; pharmaceutical preparations containing stem cells; stem cells for medical purposes; cells for medical use; stem cells; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune diseases; cell growth media for growing cells for medical use.] and 42 [Science and technology services; medical and scientific research services; scientific research and development; medical and pharmacological research services; laboratory services; analytical laboratory services; scientific services relating to the isolation and cultivation of human tissues and cells; consultancy in the field of scientific research; advisory services relating to scientific research; providing information about industrial analysis and research services; research laboratories; provision of information relating to scientific research; research and development of new products for others; scientific research for medical purposes; laboratory research services relating to pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development in the field of microorganisms and cells; clinical trials; culturing of cells for scientific research purposes; stem cell research; quality control and authentication services; providing scientific research information in the field of genetics; providing medical research information in the field of genetics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing information about the results of clinical trials for pharmaceutical products; pharmaceutical research services; development of pharmaceutical preparations and medicines; pharmaceutical products development; all of the above services provided exclusively in the fields of biotechnology, pharmaceuticals, regenerative medicine, and stem cell and gene therapy research.]

Type of Mark: Word

Date of Acceptance: June 17

Registration Advertised: Aug. 24

For further details contact Davies Collison Cave Pty. Ltd. and AWA SWEDEN AB .

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2620733.

Disclaimer: Curated by HT Syndication.